News of Note—Turnstone-La Jolla pact, Inovio-GeneOne and more

newspaper
(Pixabay)

Here is some other vaccine news of note for the week:

> Under a new collaboration, Turnstone Biologics will use La Jolla Institute for Allergy and Immunology’s neoantigen identification methods to select personalized neoantigens for the development of cancer immunotherapies. Release

> Inovio and GeneOne Life Science have dosed the first patient in a phase 1 study of GLS-6150, a vaccine that aims to boost patients’ immunity against hepatitis C. Drug Development Technology article

> After posting positive topline results, Altimmune reported that its NasoVAX intranasal influenza vaccine candidate demonstrated a durable immune response for at least six months, while significant mucosal antibodies were also observed. Release

> A team at the University of California, San Diego, is developing an acne vaccine which has passed studies on animals and human acne samples. It’s seeking a company to collaborate on a clinical trial. U.S. News & World Report article

Suggested Articles

GSK's Shingrix supply has recovered after COVID-19 prompted a slowdown in vaccinations.

To eradicate SARS-CoV-2, we'll need a vaccine that's 70% effective—and 70% of the population will need to receive it, an FDA official says.

The U.K. government, fearing losing the supply race, agreed to buy 60 million doses of GSK-Sanofi's COVID-19 vaccine even before phase 1.